Literature DB >> 22036043

Management of the malpositioned levonorgestrel-releasing intrauterine system.

Amos Ber1, Daniel S Seidman.   

Abstract

BACKGROUND: The management of a malpositioned levonorgestrel (LNG)-releasing intrauterine system (IUS) can present a clinical challenge, complicated by the high cost of replacing it with a new device. We tried to challenge the guidelines and common practice that usually suggest prompt removal of any malpositioned IUS and replacement with a new one. STUDY
DESIGN: We present our experience with 18 patients in whom the LNG-releasing IUS was found during a routine sonographic evaluation to be displaced towards the cervical canal 2 to 36 months postinsertion. Using an alligator forceps, the device was repositioned in the uterine cavity.
RESULTS: The procedure was deemed successful in 17 (94.4%) of 18 cases. In 3 (17.6%) of the 17 successful procedures, the LNG-releasing IUS was found again to be malpositioned within 2 months. No complications were noted, and no postprocedural infection occurred.
CONCLUSION: Repositioning of a malpositioned LNG-releasing IUS should be considered, as it is an easy and simple manipulation that can be done in the office with a high success rate and minimal risk of complications. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22036043     DOI: 10.1016/j.contraception.2011.09.002

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  2 in total

1.  Feasibility of LNG-IUS in a baboon model.

Authors:  Jason D Bell; Ingrid L Bergin; Melissa F Natavio; Fatima Jibrel; Melissa K Zochowski; William J Weadock; Scott D Swanson; David M Aronoff; Dorothy L Patton
Journal:  Contraception       Date:  2012-10-29       Impact factor: 3.375

2.  Effect of modified levonorgestrel-releasing intrauterine system in human adenomyosis with heavy menstrual bleeding.

Authors:  Hong Yang; Shengtan Wang; Xiaoyan Fu; Ruihong Lan; Humin Gong
Journal:  J Obstet Gynaecol Res       Date:  2021-10-21       Impact factor: 1.697

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.